Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in Richmond, Virginia.
Industry, Sector and Symbol
Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
Phone+44-1753-217800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees900
OptionableNot Optionable
Indivior (LON:INDV) Frequently Asked Questions
What is Indivior's stock symbol?
Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."
What price target have analysts set for INDV?
5 brokerages have issued 12 month target prices for Indivior's shares. Their predictions range from GBX 114 to GBX 398. On average, they expect Indivior's share price to reach GBX 234.40 in the next year. This suggests a possible upside of 97.4% from the stock's current price. View Analyst Price Targets for Indivior.
What is the consensus analysts' recommendation for Indivior?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Indivior.
Has Indivior been receiving favorable news coverage?
News articles about INDV stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Indivior earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
Who are some of Indivior's key competitors?
Some companies that are related to Indivior include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acreage (ACRGF), Activecare (ACAR), Advanced Accelerator Application (AAAP), Advanced Medical Solutions (AMS), Advanced Oncotherapy (AVO), AEGON (AGN), Airware Labs (AIRW) and Akers Biosciences (AKR).
Who are Indivior's key executives?
Indivior's management team includes the folowing people:
- Mr. Shaun Thaxter, CEO & Exec. Director
- Mr. Mark Crossley, CFO & Exec. Director
- Dr. Christian Heidbreder, Chief Scientific Officer
- Mr. Ingo Elfering, Chief Information & Innovation Officer
- Mr. Jason Thompson, VP of Investor Relations
How do I buy shares of Indivior?
Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Indivior's stock price today?
One share of INDV stock can currently be purchased for approximately GBX 118.75.
What is Indivior's official website?
How can I contact Indivior?
Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.
MarketBeat Community Rating for Indivior (LON INDV)
MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote "Outperform" if you believe INDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days.
